- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07683000
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in adults with HIV-1 whose virus is already well controlled, after 1 year (52 weeks) of treatment.
The primary objective of this study is to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus continuing an oral stable baseline regimen (SBR) in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Gilead Clinical Study Information Center
- Número de teléfono: 1-833-445-3230 (GILEAD-0)
- Correo electrónico: GileadClinicalTrials@gilead.com
Ubicaciones de estudio
-
-
Michigan
-
Berkeley, Michigan, Estados Unidos, 48072
- Reclutamiento
- Be Well Medical Center
-
-
Virginia
-
Annandale, Virginia, Estados Unidos, 22003
- Reclutamiento
- Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Key Inclusion Criteria:
Human immunodeficiency virus type 1 (HIV-1) susceptibility results from screening meeting specific criteria:
1) Proviral phenotypic susceptibility to both TAB and ZAB by the investigational protocol-defined assay at screening.
- Plasma HIV-1 RNA levels < 50 copies/mL at screening.
- At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). A single virologic elevation of ≥ 50 copies/mL and < 400 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable if the subsequent plasma HIV-1 RNA level is < 50 copies/mL.
- A plasma HIV-1 RNA test < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior.
- If > 1 plasma HIV-1 RNA measurements in the last 6 months prior to screening are available, all must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
- On a stable oral antiretroviral (ARV) therapy (ART) for ≥ 6 months prior to screening.
- A change in ART regimen ≥ 3 months prior to the screening visit for reasons other than virologic failure (eg, tolerability, simplification, drug-drug interaction profile) is allowed; individuals with a change in ART regimen ≥ 3 months prior to screening must have been on the regimen for ≥ 3 months prior to screening, and all HIV-1 RNA measurements in that period must be < 50 copies/mL. There are no permitted changes to ART regimens between screening and Day 1.
Key Exclusion Criteria:
- History of an opportunistic infection or illness indicative of Stage 3 HIV disease.
- Known hypersensitivity to the study intervention, its metabolites, or formulation excipients.
- Active, serious infections (other than HIV-1) requiring therapy < 30 days prior to randomization.
- Active tuberculosis infection.
- Acute hepatitis of any cause < 30 days before randomization.
- History of, or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or severe hepatic impairment (Child-Pugh Class C).
- Active malignancy requiring acute systemic therapy.
- Have poor venous access that would limit phlebotomy or intravenous (IV) infusion of study drugs.
- Prior use of, or exposure to, LEN or a broadly neutralizing antibody (bNAb) for HIV-1.
- Prior use of, or exposure to, long-acting (LA) injectable cabotegravir (CAB) or LA injectable rilpivirine (RPV).
- Prior use of, or exposure to, ibalizumab, fostemsavir, or maraviroc.
- Current use of, or exposure to, nevirapine or zidovudine.
- Baseline regimen consisting of monotherapy with any single ARV.
- Treatment with immunosuppressant therapies (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) within 4 weeks of screening (with the exception of a single short course of corticosteroids lasting ≤ 7 days) or have a comorbid condition with an anticipated need ongoing immunosuppressive treatment during the study.
- Hepatitis C virus (HCV) antibody positive and HCV RNA detectable.
Chronic hepatitis B virus (HBV) infection, as determined by either:
- Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
- Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
Note: Individuals found to be susceptible to HBV infection (eg, negative hepatitis B surface antibody at the screening visit, regardless of prior HBV vaccination history) should be recommended to receive an HBV vaccination. Those who remain non-immune will receive regular testing for HBV.
- Severe renal impairment-estimated glomerular filtration rate < 30 mL/min according to the Cockcroft-Gault formula.
- Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant, as determined by the investigator.
Any of the following laboratory values at screening:
- Alanine aminotransferase > 5 × upper limit of normal (ULN).
- Direct bilirubin > 1.5 × ULN
- Platelets < 50,000/mm^3.
- Hemoglobin < 8.0 g/dL.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB)
Participants will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. Every 26 weeks, participants will receive SC LEN and IV infusions of TAB and ZAB up to Week 92. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the study extension phase until completion of the extension phase, permanently discontinuing the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. |
Administrado por vía oral
Otros nombres:
Administered subcutaneously
Otros nombres:
Administered intravenously (IV)
Otros nombres:
Administered IV
Otros nombres:
|
|
Experimental: Treatment Group 2: Stable Baseline Regimen (SBR)
Participants will continue their SBR through at least Week 92. Oral SBRs will be taken per local prescribing information. After Week 92, eligible participants will have an option to switch to LEN + TAB + ZAB in the study extension phase until completion of the extension phase, permanently discounting the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. |
SBRs administered orally.
SBRs include medicines like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+ tenofovir alafenamide (TAF)+ emtricitabine (FTC).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.
Periodo de tiempo: Week 52
|
Week 52
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 92 as Defined by the US FDA Snapshot Algorithm.
Periodo de tiempo: Week 92
|
Week 92
|
|
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm.
Periodo de tiempo: Week 52
|
Week 52
|
|
Proportion of Participants With HIV-1 RNA < 50 copies/mL at Week 92 as Determined by the US FDA Snapshot Algorithm.
Periodo de tiempo: Week 92
|
Week 92
|
|
Changes from Baseline in Clusters of Differentiation 4 (CD4)+ T-cell Counts at Week 52
Periodo de tiempo: Baseline, Week 52
|
Baseline, Week 52
|
|
Changes from Baseline in CD4+ T-cell Counts at Week 92
Periodo de tiempo: Baseline, Week 92
|
Baseline, Week 92
|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
Periodo de tiempo: First dose up to 92 weeks
|
First dose up to 92 weeks
|
|
Percentage of Participants Prematurely Discontinuing Their Study Treatment due to an AE
Periodo de tiempo: First dose up to 92 weeks
|
First dose up to 92 weeks
|
|
Trough Concentrations for LEN, TAB, and ZAB at Week 26
Periodo de tiempo: Week 26
|
Week 26
|
|
Trough Concentrations for LEN, TAB, and ZAB at Week 52
Periodo de tiempo: Week 52
|
Week 52
|
|
Trough Concentrations for LEN, TAB, and ZAB at Week 104
Periodo de tiempo: Week 104
|
Week 104
|
|
Percentages of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to TAB
Periodo de tiempo: Up to 92 Weeks
|
Up to 92 Weeks
|
|
Percentages of Participants With ADAs and NAbs to ZAB.
Periodo de tiempo: Up to 92 Weeks
|
Up to 92 Weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Gilead Study Director, Gilead Sciences
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GS-US-536-6544
- 2025-524336-19 (Otro identificador: European Medicines Agency)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .